Acetyl-l-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy

Neuroscience

Volumn 167, Issue 4, 2010, Pages 1168-1174

  Vivoli, E ^a   Di Cesare Mannelli, L ^a   Salvicchi, A ^a   Bartolini, A ^a   Koverech, A ^b   Nicolai, R ^b   Benatti, P ^b   Ghelardini, C ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

Artemin; GDNF; Neurorestoration; NGF; Pain

Indexed keywords

ARTEMIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVACECARNINE; NERVE GROWTH FACTOR;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG MECHANISM; MALE; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL CORD; SPINAL GANGLION; TISSUE DISTRIBUTION;

ACETYLCARNITINE; ANALGESICS; ANIMALS; CONSTRICTION, PATHOLOGIC; GANGLIA, SPINAL; MALE; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PAIN; PAIN THRESHOLD; PERIAQUEDUCTAL GRAY; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE; SPINAL CORD;

EID: 77952553820     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.03.017     Document Type: Article

References (41)

1. Baron R. Mechanisms of disease: neuropathic pain-a clinical perspective. Nat Clin Pract Neurol 2006, 2:95-106.
2. Behbehani M.M. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 1995, 46:575-605.
3. Bennett D.L.H., Boucher T.J., Michael G.J., Popat R.J., Malcangio M., Averill S.A., Poulsen K., Priestley J.V., Shelton D.L., McMahon S.B. Artemin has potent neurotrophic actions on injured C-fibres. J Peripher Nerv Syst 2006, 11:330-345.
4. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33:87-107.
5. Bespalov M.M., Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 2007, 28:68-74.
6. Boucher T.J., Okuse K., Bennett D.L.H., Munson J.B., Wood J.N., McMahon S.B. Potent analgesic effects of GDNF in neuropathic pain states. Science 2000, 290:124-127.
7. Boucher T.J., McMahon S.B. Neurotrophic factors and neuropathic pain. Curr Opin Pharmacol 2001, 1:66-72.
8. Chen Z.Y., Chai Y.F., Cao L., Lu C.L., He C. Glial cell line-derived neurotrophic factor enhances axonal regeneration following sciatic nerve transection in adult rats. Brain Res 2001, 902:272-276.
9. Di Cesare Mannelli L., Ghelardini C., Calvani M., Nicolai R., Mosconi L., Vivoli E., Pacini A., Bartolini A. Protective effect of acetyl-L-carnitine on the apoptotic pathway of peripheral neuropathy. Eur J Neurosci 2007, 26:820-827.
10. Di Cesare Mannelli L., Ghelardini C., Calvani M., Nicolai R., Mosconi L., Toscano A., Pacini A., Bartolini A. Neuroprotective effects of acetyl-L-carnitine on neuropathic pain and apoptosis: a role for the nicotinic receptor. J Neurosci Res 2009, 87:200-207.
11. Evans J.D., Jacobs T.F., Evans E.W. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother 2008, 42:1686-1691.
12. Fang M., Wang Y., He Q.H., Sun Y.X., Deng L.B., Wang X.M., Han J.S. Glial cell line-derived neurotrophic factor contributes to delayed inflammatory hyperalgesia in adjuvant rat pain model. Neuroscience 2003, 117:503-512.
13. Fernandez E., Pallini P.R., Gangitano C., Aurora D.F., Sangiacomo C.O., Sbricioli A., Ricoy J., Rossi G.F. Effects of L-carnitine, L-acetylcarnitine and gangliosides on the regeneration of the transected sciatic nerve in rats. Neurol Res 1989, 11:57-62.
14. NGFR) mRNA level in the central nervous system of aged rats. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:117-133.
15. Galeotti N., Bartolini A., Calvani M., Nicolai R., Ghelardini C. Acetyl-L-carnitine requires phospholipase C-IP3 pathway activation to induce antinociception. Neuropharmacology 2004, 472:286-294.
16. Ghelardini C., Galeotti N., Calvani M., Mosconi L., Nicolai R., Bartolini A. Acetyl-L-carnitine induces muscarinic antinocieption in mice and rats. Neuropharmacology 2002, 43:1180-1187.
17. Gardell L.R., Wang R., Ehrenfels C., Ossipov N.H., Rossomando A.J., Miller S., Buckley C., Cai A.K., Tse A., Foley S.F., Gong B., Walus L., Carmillo P., Warley D., Huang C., Engber T., Pepinsky B., Cate R.L., Vanderah T.W., Lai J., Sah D.W., Porreca F. Multiple actions of systemic artemin in experimental neuropathy. Nat Med 2003, 9:1383-1389.
18. Gilron I., Watson P.N., Cahill C.M., Moulin D.E. Neuropathic pain: a pratical guide for the clinician. CMAJ 2006, 175:265-275.
19. Gwak Y.S., Nam T.S., Paik K.S., Hulsebosch C.E., Leem J.W. Attenuation of mechanical hyperalgesia following spinal cord injury by administration of antibodies to nerve growth factor in the rat. Neurosci Lett 2003, 336:117-120.
20. Hart A.M., Wiberg M., Youle M., Terenghi G. Systemic acetyl-L-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma. Exp Brain Res 2002, 145:182-189.
21. Hefti F.F., Rosenthal A., Walicke P.A., Wyatt S., Vergara G., Shelton D.L., Davies A.M. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006, 27:85-91.
22. Kidd P.M. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev 2008, 13:85-115.
23. Kordower J.H., Palfi S., Chen E.Y., Ma S.Y., Sendera T., Cochran E.J., Cochran E.J., Mufson E.J., Penn R., Goetz C.G., Comella C.D. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999, 46:419-424.
24. Leighton G.E., Rodriguez R.E., Hill R.G., Hughes J. kappa-opioid agonist produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. Br J Pharmacol 1988, 93:553-560.
25. Levin G.R., Rueff A., Mendell L.M. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci 1994, 6:1903-1912.
26. Li L., Xian C.J., Zhong J.H., Zhou X.F. Lumbar 5 ventral root transection-induced upregulation of nerve growth factor in sensory neurons and their target tissues: a mechanism in neuropathic pain. Mol Cell Neurosci 2003, 23:232-250.
27. McKay-Hart A., Wiberg M., Terenghi G. Pharmacological enhancement of peripheral nerve regeneration in the rat by systemic acetyl-L-carnitine treatment. Neurosci Lett 2002, 334:181-185.
28. Nagano M., Sakai A., Takahashi N., Umino M., Yoshioka K., Suzuki H. Decreased expression of glial cell line-derived neurotrophic factor signaling in rat models of neuropathic pain. Br J Pharmacol 2003, 140:1252-1260.
29. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., Lozano A.M., Penn R.D., Simpson R.K., Stacy M., Wooten G.F. Randomized double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
30. Osio M., Muscia F., Zampini L., Nascimbene C., Mailland E., Cargnel A., Mariani C. Acetyl-L-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J Peripher Nerv Syst 2006, 11:72-76.
31. Pezet S., Krzyzanowska A., Wong L.F., Grist J., Mazarakis N.D., Georgievska B., McMahon S.B. Reversal of neurochemical changes and pain-related behavior in a model of neuropathic pain using modified lentiviral vectors expressing GDNF. Mol Ther 2006, 13:1101-1109.
32. Pezet S., McMahon S.B. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006, 29:507-538.
33. Piovesan P., Pacifici L., Taglialatela G., Ramacci M.T., Angelucci L. Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res 1994, 633:77-82.
34. Pisano C., Pratesi G., Laccabue D., Zumino F., Lo Giudice P., Bellocci A., Pacifici L., Camerini B., Vesci L., Castorina M., Cocuzza S., Tredici G., Marmiroli P., Nicolini G., Galbiati S., Calvani M., Carminati P., Cavaletti G. Paclitaxel and cisplatin-induced neurotoxicity. A protective role of acetyl-L-carnitine. Clin Cancer Res 2003, 9:5756-5767.
35. Ramer M.S., French G.D., Bisby M.A. Wallerian degeneration is required for both neuropathic pain and sympatethetic sprouting into the DRG. Pain 1997, 72:71-78.
36. Sah D., Ossipov M., Porreca F. Neurotrophic factors as novel therapeutics for neuropathic pain. Nat Rev Drug Discov 2003, 2:460-472.
37. Scarpini E., Sacilotto G., Baron P., Cusini M., Scarlato G. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J Peripher Nerv Syst 1997, 2:250-252.
38. Wang R., King T., Ossipov M.H., Rossomando A.J., Vanderah T.W., Harvey P., Cariani P., Frank E., Sah D.W.Y., Porreca F. Persistent restoration of sensory function by immediate or delayed systemic artemin after dorsal root injury. Nat Neurosci 2008, 11:488-496.
39. Watson J.J., Allen S.J., Dawbarn D. Targeting nerve growth factor in pain. What is the therapeutic potential?. BioDrugs 2008, 22:349-359.
40. Woolf C.J., Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999, 353:1959-1964.
41. Zahn P.K., Subieta A., Park S.S., Brennan T.J. Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision. J Pain 2004, 5:157-163.